Aquatic Capital Management’s Axsome Therapeutics AXSM Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
– Sell
-16,297
Closed -$3.99M – 1237
2026
Q2
$3.99M Buy
+16,297
New +$3.53M 0.14% 190
2025
Q4
– Sell
-7,426
Closed -$902K – 1406
2025
Q3
$902K Sell
7,426
-16,208
-69% -$1.83M 0.02% 701
2025
Q2
$2.47M Sell
23,634
-23,812
-50% -$2.52M 0.05% 415
2025
Q1
$5.53M Buy
47,446
+46,543
+5,154% +$5.3M 0.14% 195
2024
Q4
$76.4K Buy
+903
New +$83K ﹤0.01% 1114
2024
Q3
– Sell
-5,200
Closed -$419K – 1145
2024
Q2
$419K Buy
+5,200
New +$385K 0.02% 583
2024
Q1
– Sell
-14,100
Closed -$1.12M – 1226
2023
Q4
$1.12M Buy
+14,100
New +$943K 0.03% 449
2023
Q2
– Sell
-4,500
Closed -$278K – 1332
2023
Q1
$278K Buy
+4,500
New +$296K 0.02% 522
2022
Q2
– Sell
-700
Closed -$29K – 1197
2022
Q1
$29K Buy
+700
New +$21.7K 0.04% 397

Other funds holding AXSM

Aquatic Capital Management's AXSM Position: Q3 2026 in Review

Aquatic Capital Management sold out of Axsome Therapeutics (AXSM) in Q3 2026, closing a stake of 16,297 shares — an estimated $3.99M sold.

Aquatic Capital Management first reported a position in AXSM in Q1 2022 and held it in 9 quarters. The position peaked at $5.53M in Q1 2025. 466 funds tracked by Wall St. Rank hold AXSM as of Q3 2026.

  • Aquatic Capital Management reported no remaining Axsome Therapeutics position as of Q3 2026 after selling out during the quarter.
  • Aquatic Capital Management sold 16,297 Axsome Therapeutics shares in Q3 2026, an estimated $3.99M.
  • Aquatic Capital Management first reported a position in Axsome Therapeutics in Q1 2022 and held it in 9 quarters.
  • Aquatic Capital Management's Axsome Therapeutics position peaked at $5.53M in Q1 2025.
  • 466 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q3 2026.

Based on Aquatic Capital Management's 13F filing for Q3 2026, filed 16 Nov 2026.